Dear All: It was a HUGE day at the Pew Charitable Trusts today! First, Commissioner Scott Gottleib gave a superb and very exciting speech. You can either read or listen to the entire speech. There is also a panel discussion after his talk that is worth replaying. Here are some highlights from Commissioner Gottleib’s talk: FDA is working to coordinate
Dear All: For your weekend reading list, I have some papers on the topic of (mostly pull) incentives for antibiotics. First, I previously wrote about the survey from TATFAR (Transatlantic Task Force on Antimicrobial Resistance) of 6 possible pull models (higher reimbursement, diagnostic confirmation, market entry rewards both fully and partially delinked, tradable exclusivity vouchers, and an options market).
Dear All: I’ve written a lot about the need for pull incentives, preferably delinked (some papers to read, comments by TATFAR, highlights from Davos 2018, and the UK commits to trying delinkage). Now, I am delighted to report that a really serious effort is underway in the US to make something happen during the 116th Congress. The essential document can be
Dear All: We can’t say it too often … our current approach to buying antibiotics is broken in that it is tantamount to paying the firemen on a per-fire basis. We simply must change this! Driving this change requires persistent effort on the part of many. Over the past few days we’ve had two welcome additions to
Dear All: The TATFAR group has a new and very helpful paper out in Clinical Infectious Diseases in which they analyze 6 different kinds of pull incentives: Higher reimbursement Diagnosis confirmation (lower cost for a few days of empiric therapy, higher cost if diagnostics confirm ongoing need) A fully delinked market entry reward (no sales-based income) A